EFFICACY AND ADVERSE REACTIONS OF FIRST-LINE TREATMENT WITH PEMETREXED AND CISPLATIN IN ADVANCED LUNG ADENOCARCINOMA

被引：0
|
作者：
Wang, Dawei [1 ]
Wei, Mingchao [2 ]
机构：
[1] Yantai Mt Hosp, Dept Thorac Surg, Yantai, Peoples R China
[2] Binzhou Med Univ, Yantai Affiliated Hosp, Dept Thorac Surg, Yantai, Peoples R China
来源：
JOURNAL OF INVESTIGATIVE MEDICINE | 2023年 / 71卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
20
引用
收藏
页码：8 / 9
页数：2
相关论文
共 50 条
  • [1] PEMETREXED VERSUS GEMCITABINE IN COMBINATION WITH CARBOPLATIN AS FIRST-LINE TREATMENT OF ADVANCED LUNG ADENOCARCINOMA
    Shee, C. Chee
    Liam, C. K.
    Pang, Y. K.
    Kow, K. S.
    Wong, C. K.
    Poh, M. E.
    Tan, J. L.
    RESPIROLOGY, 2016, 21 : 111 - 111
  • [2] Efficacy and safety of immune checkpoint inhibitor without pemetrexed for first-line maintenance therapy in advanced lung adenocarcinoma
    Gao, Ming
    Yang, Wenyu
    Wang, Chunyu
    Wang, Ting
    Jing, Fangfang
    Zhang, Fan
    Tao, Haitao
    Ma, Junxun
    Hu, Yi
    Wang, Lijie
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [3] EFFICACY AND SAFETY OF CISPLATIN/PEMETREXED AS FIRST-LINE TREATMENT FOR JAPANESE PATIENTS WITH ADVANCED NONSQUAMOUS NON-SMALL CELL LUNG CANCER
    Yamaguchi, Teppei
    Nakanishi, Toru
    Hayashi, Masamichi
    Isogai, Sumito
    Hoshino, Tami
    Mieno, Yuki
    Uozu, Sakurako
    Morishita, Mariko
    Okamura, Takuya
    Takeyama, Tomoko
    Minezawa, Tomoyuki
    Morikawa, Sayako
    Niwa, Yoshikazu
    Okazawa, Mitsushi
    Imaizumi, Kazuyoshi
    RESPIROLOGY, 2013, 18 : 83 - 83
  • [4] Efficacy and safety of pemetrexed/cisplatin versus gemcitabine/cisplatin as first-line treatment in Chinese patients with advanced nonsquamous non-small cell lung cancer
    Wu, Yi-Long
    Lu, Shun
    Cheng, Ying
    Zhou, Caicun
    Wang, Mengzhao
    Qin, Shukui
    Lu, You
    Zhang, Yang
    Zhu, Yunzhong
    Song, Xiangqun
    Wang, Xin
    Barraclough, Helen
    Zhang, Xiaoqing
    Chi, Haidong
    Orlando, Mauro
    LUNG CANCER, 2014, 85 (03) : 401 - 407
  • [5] Efficacy and safety of pemetrexed plus cisplatin as first-line chemotherapy in advanced malignant peritoneal mesothelioma
    Nagata, Yusuke
    Sawada, Ryoichi
    Takashima, Atsuo
    Shoji, Hirokazu
    Honma, Yoshitaka
    Iwasa, Satoru
    Amano, Katsushi
    Kato, Ken
    Hamaguchi, Tetsuya
    Shimada, Yasuhiro
    Saruta, Masayuki
    Boku, Narikazu
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2019, 49 (11) : 1004 - 1008
  • [6] Sequential treatment of icotinib after first-line pemetrexed in advanced lung adenocarcinoma with unknown EGFR gene status
    Zheng, Yulong
    Fang, Weijia
    Deng, Jing
    Zhao, Peng
    Xu, Nong
    Zhou, Jianying
    JOURNAL OF THORACIC DISEASE, 2014, 6 (07) : 958 - 964
  • [7] Weiterbehandlung mit Pemetrexed nach first-line Pemetrexed/Cisplatin
    best practice onkologie, 2011, 6 (4) : 23 - 23
  • [8] Pemetrexed with Cisplatin as First-line Therapy for NSCLC
    Dickgreber, N. J.
    PNEUMOLOGE, 2009, 6 (03): : 176 - 178
  • [9] Clinical Characteristics and Outcome for Patients with Advanced Lung Adenocarcinoma Treated with First-Line Pemetrexed Plus Platinum
    Ji, X.
    Hu, X.
    Zhu, Y.
    Liu, Y.
    Lin, L.
    Xing, P.
    Hao, X.
    Wang, Y.
    Li, J.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S885 - S885
  • [10] First-line icotinib versus pemetrexed plus cisplatin on quality of life and safety in elderly patients with EGFR-mutated advanced lung adenocarcinoma
    Ye, Yongjun
    Han, Lifeng
    Yu, Hongyan
    Song, Lihong
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2019, 12 (09): : 11819 - 11824
12345